Business
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021
Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET PORTLAND, Maine, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:
About this update from Immucell Corporation
[{"type":"text","content":"Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET\nPORTLAND, Maine, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter and year ended December 31, 2021 after the market closes on Tuesday, February 22, 2022. The Company has scheduled a conference call the next morning, Wednesday, February 23, 2022, at 9:00 AM ET to review the financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available for seven days at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing confirmation #7112153. Ms. Elizabeth L. Williams, VP of Manufacturing Operations, is expected to join the call to discuss the Company’s investments to increase its production capacity for the First Defense® product line, and Ms. Bobbi Jo Brockmann, VP of Sales and Marketing, is expected to join the call to discuss the drivers behind the market demand for the First Defense® product line and the Company’s preliminary thoughts regarding the launch of Re-Tain®. The Company expects to file its Annual Report on Form 10-K on or around Wednesday, March 30, 2022. Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which will be posted under the “Investors” tab of the Company’s website at www.immucell.com after the market closes on Tuesday, February 22, 2022, or by request to the Company. About ImmuCell:ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics. Press releases and other information about t...